Latest News
Zevra Therapeutics, Inc.
- Zevra Therapeutics, Inc. Estimates – HAN:1GDA
- Zevra Therapeutics to report Q3FY26 results on November 3
- Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call
- Form 144 Zevra Therapeutics For: 17 October By Investing.com
- Zevra Therapeutics: Cash Plus A Drug Priced Below Its Rival's Deal (NASDAQ:ZVRA)
- Zevra Therapeutics president and CEO sells $224,948 in stock By Investing.com
- A 20,000-share sale was reported by Zevra Therapeutics (ZVRA) director Neil F. McFarlane.
- Zevra Therapeutics shares new clinical findings for Niemann Pick disease type C
- Zevra Therapeutics posts 53% revenue growth in 2Q26 driven by Miplyffa's strong US sales
- Zevra Therapeutics: Miplyffa Validates The Bull Case, Europe Still The Swing Factor (ZVRA)
Headlines from the last 30 days, linking to the original publishers. See all market news →